Identification of a highly lethal V3+TP53+subset in ALK+lung adenocarcinoma-Reference-Cited by-同舟云学术

Identification of a highly lethal V3+TP53+subset in ALK+lung adenocarcinoma

Published:2018-10-30 Issue:1 Volume:144 Page:190-199
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Christopoulos P.¹²,Kirchner M.³,Bozorgmehr F.¹⁴,Endris V.³^ORCID,Elsayed M.¹,Budczies J.³^ORCID,Ristau J.⁴,Penzel R.³,Herth F.J.²⁵,Heussel C.P.²⁶,Eichhorn M.²⁷,Muley T.²⁸,Meister M.²⁸,Fischer J.R.⁹,Rieken S.⁴,Lasitschka F.²³,Bischoff H.¹,Sotillo R.²¹⁰,Schirmacher P.³,Thomas M.¹²^ORCID,Stenzinger A.²³^ORCID

Affiliation:

1. Department of Thoracic Oncology; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

2. Translational Lung Research Center Heidelberg (TLRC-H); Heidelberg Germany, member of the German Center for Lung Research (DZL)

3. Institute of Pathology, Heidelberg University Hospital; Heidelberg Germany

4. Department of Radiation Oncology; Heidelberg University Hospital; Heidelberg Germany

5. Department of Pneumology; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

6. Department of Diagnostic and Interventional Radiology with Nuclear Medicine; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

7. Department of Surgery; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

8. Translational Research Unit; Thoraxklinik at Heidelberg University Hospital; Heidelberg Germany

9. Department of Thoracic Oncology; Lungenklinik Löwenstein; Löwenstein Germany

10. Division of Molecular Thoracic Oncology; German Cancer Research Center; Heidelberg Germany

Funder

German Cancer Consortium (DKTK)

Deutsche Zentrum für Lungenforschung

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ijc.31893/fullpdf

Reference35 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice;Caccese;Expert Opin Pharmacother,2016

3. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study;Duruisseaux;Oncotarget,2017

4. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer;Noh;J Pathol,2017

5. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ NSCLC;Christopoulos;Int J Cancer,2018

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study;European Journal of Cancer;2024-11

2. EML4-ALK variant-specific genetic interactions shape lung tumorigenesis;2024-08-27

3. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database;Journal of Thoracic Oncology;2024-07

4. Comparing Genomic Profiles of ALK Fusion-Positive and ALK Fusion-Negative Nonsmall Cell Lung Cancer Patients;Global Medical Genetics;2024-06

5. Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome;Drug Resistance Updates;2024-05